Concepedia

Kentaro Miyake

KM

85

Publications

2.8K

Citations

33

H-Index

1993

Active since

Affiliations

University of California San Diego(Current)

AntiCancer (United States)

University of California, Los Angeles

Yokohama City University

Kanazawa University

Kentaro Miyake is an author at University of California San Diego specializing in medicine, tumor biology, and oncology.

ORCID

Top concepts

Publications per year

1993–2023

85

Publications

85

Clinical Practice Guidelines for Pancreatic Cancer 2022 from the Japan Pancreas Society: a synopsis

Takuji Okusaka, Masahiro Yoshida, Masayuki Kitano et al. · International Journal of Clinical Oncology · 2023 · 153 citations · Full text

Oral recombinant methioninase (o-rMETase) is superior to injectable rMETase and overcomes acquired gemcitabine resistance in pancreatic cancer

Kei Kawaguchi, Kentaro Miyake, Qinghong Han et al. · Cancer Letters · 2018 · 85 citations

, , +6

Histone methylation status of H3K4me3 and H3K9me3 under methionine restriction is unstable in methionine-addicted cancer cells, but stable in normal cells

Jun Yamamoto, Qinghong Han, Sachiko Inubushi et al. · Biochemical and Biophysical Research Communications · 2020 · 83 citations

, , +11

Recombinant methioninase effectively targets a Ewing's sarcoma in a patient-derived orthotopic xenograft (PDOX) nude-mouse model

Takashi Murakami, Shukuan Li, Qinghong Han et al. · Oncotarget · 2017 · 81 citations · Full text

Combination treatment with recombinant methioninase enables temozolomide to arrest a BRAF V600E melanoma in a patient-derived orthotopic xenograft (PDOX) mouse model

Kei Kawaguchi, Kentaro Igarashi, Shukuan Li et al. · Oncotarget · 2017 · 73 citations · Full text

Rows per page

1–5 of 85